ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,223.60
-2.18%
S&P 500
5,348.08
-0.09%
Dow Jones
38,857.28
-0.07%
US Dollar vs Yen
156.628
0.59%
Brent Oil
79.525
-0.44%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Atara Biotherapeutics Inc (ATRA)

  7. Atara Biotherapeutics Inc (ATRA) ニュース

ATRA

Atara Biotherapeutics (ATRA)

Atara Biotherapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ATRA
日付受信時刻ニュースソース見出しコード企業名
2024/06/0605 : 01Business WireAtara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/3005 : 01Business WireAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/2307 : 18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/2109 : 34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/2109 : 34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/2109 : 33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/2109 : 33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/2109 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/2022 : 25Business WireAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDANASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
2024/05/1710 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATRA

最近閲覧した銘柄

NYSE
MRK
Merck
FX
USDJPY
US Dollar vs Yen
FX
USDEUR
US Dollar vs Euro
PM
XAUUSD
Gold vs US Dollar
NASDAQ
AAPL
Apple
NASDAQ
TSLA
Tesla
USOTC
BNPQY
BNP Paribas (QX)
NYSE
XOM
Exxon Mobil
CCOM
US500
US 500
USOTC
RHHBY
Roche (QX)
NYSE
NKE
Nike
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US30
US 30
SPI
SP500
S&P 500
NYSE
KO
Coca Cola
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有